Overview

Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)

Status:
Completed

Trial end date:
2000-12-26

Target enrollment:

Participant gender:

Summary

The primary objectives were to assess the safety and tolerability of twice daily (BID) doses of 65 mg cinacalcet administered orally to adults with primary HPT.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Cinacalcet
Cinacalcet Hydrochloride